Last $43.61 USD
Change Today -0.06 / -0.14%
Volume 4.1M
As of 8:04 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Key Developments

Novartis To Sell Unit Being Built In Pernambuco

Novartis AG (SWX:NOVN) will no longer pursue the project being built in Pernambuco. Valor has learned that Novartis is seeking companies interested in taking over the unit, which is being built in Jaboatão dos Guararapes. One company possibly interested in acquiring the plant would be GlaxoSmithKline plc (LSE:GSK).

GlaxoSmithKline Seeking Bids By Next Month For Older Drugs

GlaxoSmithKline plc (LSE:GSK) is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Potential bidders include Kohlberg Kravis Roberts & Co. L.P. (NYSE:KKR), Lupin Limited (BSE:500257) and H. Lundbeck A/S (CPSE:LUN) all of which are interested in acquiring rights to products in certain regions. Lundbeck is reviewing a bid for products marketed in North America as it seeks to expand there, two of the sources said. KKR has teamed up with Norgine B.V. in a bid to acquire some of GSK's drugs sold in Europe, said the same people. Lupin is also expected to participate in the second round of the auction and would be interested in products in the United States, said the sources. Other private equity funds with an interest in healthcare are also looking at some specific products. Some bidders might still emerge with an interest in the entire portfolio, although this scenario is seen as less likely. The sources said GSK was looking for a multiple of more than two times sales, suggesting a price of at least $3.2 billion. GSK, which is being advised by Lazard, aims to find buyers by the end of 2014. GSK, Lundbeck, KKR and Norgine all declined to comment.

Brian McNamara to Join GSK as Head of Americas and Europe for Consumer Health Businesses

Brian McNamara, currently Division Head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses, reporting to the President of GSK Consumer Healthcare.

GlaxoSmithKline plc Appoints Urs Rohner to its Board as Non-Executive Director, Effective January 1, 2015

GlaxoSmithKline plc announced the appointment of Mr. Urs Rohner to its Board as a Non-Executive Director, effective January 1, 2015. On appointment, Mr. Rohner will also become a member of GSK's Remuneration Committee. Mr. Rohner is currently Chairman of Credit Suisse Group AG. Mr. Rohner was appointed Chairman of Credit Suisse in 2011 following a number of senior positions at the company including General Counsel and Chief Operating Officer.

GlaxoSmithKline Announces Results from Phase III Tafinlar Study in BRAF V600E-Mutant Metastatic Melanoma

GlaxoSmithKline has announced updated results from the Phase III BREAK-3 trial showing that 45% of patients with BRAF V600E-mutant metastatic melanoma receiving treatment with dabrafenib (Tafinlar) were alive at two years as opposed to 32% of patients receiving treatment with dacarbazine (DTIC). The company noted that 59% patients in the DTIC arm whose disease progressed consequently received treatment with dabrafenib; these patients were included in the results for the DTIC control arm. The median overall survival (OS) at the planned two-year follow up was 20.0 months for the dabrafenib versus 15.6 months for the DTIC arm. The company presented data at the European Society for Medical Oncology 2014 Congress in Spain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $43.61 USD -0.06

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $137.60 USD +0.20
AbbVie Inc $54.41 USD +1.04
Amgen Inc $137.51 USD +3.82
Bayer AG €103.15 EUR +0.39
Novo Nordisk A/S kr261.20 DKK +0.40
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 13.1x
Price/Sales 2.5x
Price/Book 10.0x
Price/Cash Flow 13.0x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.